| Bioactivity | SSK1, a senescence-specific killing compound, is a β-galactosidase-targeted prodrug attenuates inflammation. SSK1 is activated by lysosomal β-galactosidase and selectively killed senescent cells through the activation of p38 MAPK and induction of apoptosis[1]. |
| Invitro | SSK1 (0.5 µM; 12-72 hours) activates the phosphorylation levels of both p38 MAPK and MKK3/MKK6 in senescent cells. SSK1 kills senescent cells through the activation of the p38 MAPK signaling pathway. SSK1 is able to induce mitochondrial DNA damage in senescent cells[1]. SSK1 (0.01-1 µM; 3 days) selectively and potently eliminates β-galactosidase-positive senescent cells within a wide therapeutic window[1]. Cell Proliferation Assay[1] Cell Line: |
| Name | SSK1 |
| CAS | 2629250-69-5 |
| Formula | C31H34F2N4O18 |
| Molar Mass | 788.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |